Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

1.4K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.4K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

933
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
933
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

378
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
378
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

402
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
402
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

868
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
868
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

406
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
406

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal effects of comorbidities on brain structure and cognition in older breast cancer survivors.

Journal of the National Cancer Institute·2026
Same author

Examining bidirectional longitudinal relationships between physical activity and physical function in older breast cancer survivors: The Thinking and Living with Cancer study.

Cancer·2026
Same author

Rationale and study protocol for a randomized controlled MIND diet feeding trial for breast cancer-related cognitive impairment.

Contemporary clinical trials·2026
Same author

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Bone marrow transplantation·2026
Same author

Homework adherence in exposure-based CBT for youth with obsessive-compulsive disorder: Clinical outcomes and predictors across treatment.

Behaviour research and therapy·2026
Same author

Interaction of endocrine therapy for breast cancer with APOE4 status on cognition over 5-year follow-up.

JNCI cancer spectrum·2026

Related Experiment Video

Updated: May 6, 2026

Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
07:01

Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment

Published on: September 20, 2020

3.9K

Nutraceutical intervention improves older adults' cognitive functioning.

Brent J Small1, Kerri S Rawson, Christina Martin

  • 11 School of Aging Studies, University of South Florida , Tampa, Florida.

Rejuvenation Research
|October 19, 2013
PubMed
Summary
This summary is machine-generated.

This study found that a nutraceutical (NT-020) containing blueberry and other ingredients improved processing speed in older adults. Cognitive function in the placebo group did not change, suggesting NT-020 may support brain health.

More Related Videos

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

6.3K
Orienteering as a Tool for Cognitive Research: An Implementation Guide
07:13

Orienteering as a Tool for Cognitive Research: An Implementation Guide

Published on: November 29, 2024

1.8K

Related Experiment Videos

Last Updated: May 6, 2026

Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
07:01

Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment

Published on: September 20, 2020

3.9K
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

6.3K
Orienteering as a Tool for Cognitive Research: An Implementation Guide
07:13

Orienteering as a Tool for Cognitive Research: An Implementation Guide

Published on: November 29, 2024

1.8K

Area of Science:

  • Gerontology
  • Nutritional Neuroscience
  • Cognitive Health

Background:

  • Cognitive decline in aging is a significant concern.
  • Interventions to maintain cognitive function in older adults are crucial.
  • Nutraceuticals offer a potential avenue for cognitive support.

Purpose of the Study:

  • To evaluate the impact of a novel nutraceutical (NT-020) on cognitive function in healthy older adults.
  • To assess changes in multiple cognitive domains, including memory, processing speed, and executive function.
  • To determine the safety and tolerability of NT-020 in this population.

Main Methods:

  • A double-blind, placebo-controlled clinical trial was conducted.
  • 105 cognitively intact adults (65-85 years) received either NT-020 or a placebo for 2 months.
  • Cognitive performance was assessed using a battery of tests across six domains at baseline and follow-up.

Main Results:

  • Participants taking NT-020 showed significant improvements in processing speed compared to the placebo group.
  • No significant changes were observed in other cognitive domains (episodic memory, verbal ability, working memory, executive functioning, complex speed).
  • NT-020 was well-tolerated, with no significant difference in adverse events between groups.

Conclusions:

  • The nutraceutical NT-020 demonstrated a positive effect on processing speed in older adults.
  • These findings suggest NT-020 may be a promising intervention for supporting cognitive health in aging.
  • Further research is warranted to explore the long-term effects and mechanisms of action.